News In Brief: Cheap American Drugs Replaced; EMA, FDA Differ on Toansa; Apotex Warned; Cheaper Drug Recalls
This article was originally published in The Gold Sheet
“Cheap China drugs” paradigm turned on its head; EMA disagrees with FDA on Ranbaxy site; Apotex API site fails FDA test; Drug tracing will mean cheaper recalls.
You may also be interested in...
Persistent data integrity and quality unit failures at two Apotex plants in Bangalore, India, led to wholesale US market withdrawals by the Canadian generic drug manufacturer.
The specialty generic manufacturer has a facility dedicated to producing shortage drugs, a seemingly endless commercial opportunity given the development, regulatory and reimbursement challenges in the sterile injectable space.
Sanofi seeks to delay decision clearing path for Mylan's Lantus biosimilar; says it should be able to get rehearing based on Federal Circuit's ruling that PTAB judges were not constitutionally appointed.